C
7.34
-3.43 (-31.85%)
| Previous Close | 10.77 |
| Open | 8.51 |
| Volume | 18,756,545 |
| Avg. Volume (3M) | 1,325,596 |
| Market Cap | 653,493,440 |
| Price / Earnings (Forward) | 21.74 |
| Price / Sales | 50.82 |
| Price / Book | 11.13 |
| 52 Weeks Range | |
| Earnings Date | 7 May 2025 - 12 May 2025 |
| Operating Margin (TTM) | -28.69% |
| Diluted EPS (TTM) | -0.800 |
| Total Debt/Equity (MRQ) | 0.95% |
| Current Ratio (MRQ) | 3.96 |
| Operating Cash Flow (TTM) | -55.75 M |
| Levered Free Cash Flow (TTM) | -39.78 M |
| Return on Assets (TTM) | -37.69% |
| Return on Equity (TTM) | -65.04% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | CorMedix Inc. | Bearish | Bullish |
AIStockmoo Score
0.6
| Analyst Consensus | 1.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | 0.63 |
|
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company’s focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 1.25% |
| % Held by Institutions | 39.99% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| First Turn Management, Llc | 31 Dec 2024 | 1,021,421 |
| J. Goldman & Co Lp | 31 Dec 2024 | 457,320 |
| Palisades Investment Partners, Llc | 31 Dec 2024 | 364,019 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 18.00 (Leerink Partners, 145.23%) | Buy |
| Median | 13.50 (83.92%) | |
| Low | 12.00 (Needham, 63.49%) | Buy |
| 12.00 (RBC Capital, 63.49%) | Buy | |
| Average | 14.25 (94.14%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 8.18 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Needham | 26 Mar 2025 | 12.00 (63.49%) | Buy | 7.34 |
| RBC Capital | 26 Mar 2025 | 12.00 (63.49%) | Buy | 7.34 |
| D. Boral Capital | 25 Mar 2025 | 15.00 (104.36%) | Buy | 7.34 |
| 05 Mar 2025 | 15.00 (104.36%) | Buy | 10.11 | |
| Leerink Partners | 07 Mar 2025 | 18.00 (145.23%) | Buy | 10.71 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 25 Mar 2025 | Announcement | CorMedix Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update |
| 18 Mar 2025 | Announcement | CorMedix Inc. to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 25, 2025 |
| 21 Jan 2025 | Announcement | CorMedix Announces Collaboration for DefenCath Promotion to the VA and Other Federal Facilities |
| 07 Jan 2025 | Announcement | CorMedix Inc. Announces Preliminary Fourth Quarter 2024 Results and Provides Business Update |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |